AbbVie Inc.

ABBV: Somewhat-Bullish (0.349)

Relevance 0.626

ABC11 News•7/13/2026

AbbVie pharmaceutical project moves forward in Durham: 'Huge deal'

Bullish (0.433)

ABBV: Bullish (0.442)

Stock Titan•7/13/2026

Apogee Therapeutics (NASDAQ: APGE) backs AbbVie’s $135.11‑per‑share all‑cash deal

Bullish (0.380)

ABBV: Bullish (0.412)

Relevance 0.984

GuruFocus•7/13/2026

ABBV Maintained by UBS -- Price Target Raised to $260

Neutral (0.031)

ABBV: Neutral (0.046)

marketscreener.com•7/13/2026

BMO Capital Adjusts Price Target on AbbVie to $300 From $258, Maintains Outperform Rating

Bullish (0.383)

ABBV: Bullish (0.410)

24/7 Wall St.•7/13/2026

The Real Case for Buying Johnson & Johnson (JNJ) Before July 15

Johnson & Johnson (JNJ) is presenting a strong buy case ahead of its July 15 earnings report, thanks to its consistent earnings beats, robust revenue growth, diversified portfolio including a growing MedTech segment, and a history of dividend increases. The company's strategic pipeline, high probability of Q2 earnings beat according to Polymarket traders, and positive Wall Street analyst ratings further support its appeal compared to alternatives like AbbVie and Pfizer. The article highlights JNJ's stability as a Dividend King and its accelerated growth even amidst challenges like STELARA erosion.

Neutral (0.135)

ABBV: Somewhat-Bullish (0.245)

Relevance 0.706

Yahoo Finance•7/12/2026

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

AbbVie, though relatively young as a standalone company, has maintained its dividend growth inherited from Abbott, positioning itself as a Dividend King. The acquisition of Apogee Therapeutics for $10.9 billion is a strategic move to bolster its drug pipeline, particularly with drugs like zumilokibart for atopic dermatitis and a pipeline in the respiratory space. This acquisition, along with its consistent revenue from products like Botox, demonstrates AbbVie's commitment to sustaining its long-term dividend growth and competing with older drug-makers.

Somewhat-Bullish (0.179)

ABBV: Somewhat-Bullish (0.322)

ad-hoc-news.de•7/12/2026

AbbVie stock holds steady after a new U.S. market backdrop

AbbVie Inc. (US00287Y1091) remains a significant U.S. healthcare company, focusing on its diversified drug portfolio with strong exposure to immunology and aesthetics. The stock's stability is attributed to its broad therapeutic franchise, multiple revenue streams, and established U.S. distribution, which helps mitigate single-product risks and market volatility. While Humira was a historical cornerstone, the company's valuation now reflects its cash flow, dividend appeal, and pipeline execution driven by newer growth drivers.

Somewhat-Bullish (0.318)

ABBV: Somewhat-Bullish (0.311)

The Globe and Mail•7/12/2026

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

This article compares two ETFs: State Street Health Care Select Sector SPDR ETF (XLV) and Invesco Nasdaq Biotechnology ETF (IBBQ), for investors seeking healthcare exposure. XLV offers broad stability with lower costs and volatility, tracking 60 S&P 500 healthcare stocks, while IBBQ provides concentrated exposure to the biotech subsector with higher historical returns but also higher volatility and expense ratios. The analysis details their respective holdings, expense ratios, dividend yields, performance, and risk metrics to help investors choose based on their risk tolerance and investment goals.

Somewhat-Bullish (0.287)

ABBV: Somewhat-Bullish (0.288)

Relevance 0.578

The Globe and Mail•7/12/2026

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

AbbVie, though a relatively young stand-alone company, has maintained its Dividend King status by strategically acquiring new drug candidates. Its recent $10.9 billion deal to buy Apogee Therapeutics is critical for expanding its drug pipeline, particularly with zumilokibart for atopic dermatitis and drugs in the respiratory space, ensuring future revenue streams as current patents expire. This acquisition strategy, similar to its successful integration of Botox, strengthens AbbVie's long-term competitive edge in the pharmaceutical industry.

Somewhat-Bullish (0.347)

ABBV: Bullish (0.546)

The Motley Fool•7/11/2026

Which is the Better Choice for Healthcare Investors? IYH or BBH?

This article compares two healthcare-focused ETFs, iShares U.S. Healthcare ETF (IYH) and VanEck Biotech ETF (BBH), for investors. IYH offers broader exposure to the healthcare sector with 100 holdings and lower volatility, while BBH focuses on fewer biotechnology firms, offering higher growth potential but also greater volatility. The analysis details their costs, performance, risk, and core holdings to help investors decide based on their preferences for stability versus growth.

Somewhat-Bullish (0.205)

ABBV: Somewhat-Bullish (0.202)

Relevance 0.605

The Globe and Mail•7/11/2026

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

This article compares two healthcare-focused ETFs: State Street Health Care Select Sector SPDR ETF (XLV) and Invesco Nasdaq Biotechnology ETF (IBBQ). XLV offers broad exposure to the healthcare sector with lower costs and volatility, while IBBQ provides focused exposure to biotechnology with higher historical returns but also higher volatility. The article highlights their differences in expense ratios, holdings, and risk profiles to help investors choose based on their preference for stability versus thematic growth.

Somewhat-Bullish (0.242)

ABBV: Somewhat-Bullish (0.259)

Relevance 0.666

The Globe and Mail•7/11/2026

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)?

This article compares two healthcare-focused ETFs: the State Street Health Care Select Sector SPDR ETF (XLV) and the Invesco Nasdaq Biotechnology ETF (IBBQ). XLV offers broad, stable exposure to the healthcare sector with lower costs and established megacap holdings, while IBBQ provides concentrated, higher-growth potential in the volatile biotechnology sector. Investors must weigh stability and lower costs against higher historical returns and greater risk when choosing between these funds.

Somewhat-Bullish (0.263)

ABBV: Somewhat-Bullish (0.280)

Relevance 0.739

The Globe and Mail•7/11/2026

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Eli Lilly & Co (LLY)

Bank of America Securities analysts have maintained bullish ratings on two major healthcare companies. Tim Anderson reiterated a Buy rating for AbbVie (ABBV) with a price target of $276, while Jason Gerberry assigned a Buy rating to Eli Lilly & Co (LLY) with a $1334 price target, both implying potential upside from current levels. Both companies hold a consensus of "Strong Buy" among analysts.

Bullish (0.413)

ABBV: Bullish (0.430)

Moomoo•7/11/2026

BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $276

BofA Securities has upgraded its rating for AbbVie (ABBV.US) to "Buy" from "Neutral." The firm also increased its price target for AbbVie's stock to $276. This upgrade reflects a positive outlook on the biopharmaceutical company's future performance.

Bullish (0.409)

ABBV: Bullish (0.425)

Simply Wall Street•7/11/2026

West Pharmaceutical Services (WST) Sells SmartDose Rights, Is The Stock Fully Priced?

West Pharmaceutical Services (WST) has sold its SmartDose 3.5mL On Body Delivery System rights and related facilities to AbbVie, enabling the company to refocus on core drug delivery offerings. Despite strong short-term stock performance, the company's valuation is viewed as only modestly undervalued, with a P/E ratio significantly higher than market and peer averages. Investors are encouraged to seek further insights into the company's valuation and risks.

Neutral (0.126)

Simply Wall Street•7/11/2026

ABBV: Neutral (0.119)

Relevance 0.629

West Pharmaceutical Services (WST) Sells SmartDose Rights, Is The Stock Fully Priced?

West Pharmaceutical Services (WST) has sold its SmartDose 3.5mL On Body Delivery System rights to AbbVie, shifting focus to core drug delivery. While the company has seen strong 1-year share price momentum, analysts are divided on its current valuation, with one narrative suggesting a slight undervaluation and another indicating it's significantly overvalued based on its P/E ratio. Investors are encouraged to review the underlying data to determine if current levels justify investment.

Somewhat-Bullish (0.194)

ABBV: Somewhat-Bullish (0.214)

Relevance 0.618

Investing.com•7/11/2026

Apogee Therapeutics CEO Michael Henderson sells $2.67m in stock

Apogee Therapeutics CEO Michael Henderson sold 20,000 shares of company stock worth $2.67 million and gifted 75,046 shares to a donor-advised fund. These transactions occurred as Apogee Therapeutics stock trades near its 52-week high, having gained 250% in the last year, and follows the company's agreement to be acquired by AbbVie for $10.9 billion.

Neutral (0.072)

ABBV: Somewhat-Bullish (0.312)

Relevance 0.718

24/7 Wall St.•7/10/2026

Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner

Johnson & Johnson (JNJ) and AbbVie (ABBV) both reported Q1 2026 earnings, showcasing different strategies for pharma dominance. JNJ delivered a strong quarter with oncology growth and its 64th consecutive dividend hike, appealing to risk-averse income investors. AbbVie, while demonstrating significant revenue growth driven by Skyrizi and Rinvoq, faced an EPS miss due to a pipeline charge, making it more attractive to growth-plus-income buyers willing to tolerate more volatility.

Neutral (0.118)

ABBV: Somewhat-Bullish (0.341)

Yahoo Finance UK•7/10/2026

West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business

West Pharmaceutical Services (WST) has sold the rights and facilities for its SmartDose 3.5 mL On Body Delivery System to AbbVie, aiming to refocus its business on other high-value drug delivery platforms. This move allows West to concentrate on larger volume on-body delivery solutions and GLP-1 related devices, supporting its strategy to streamline its portfolio and reduce operational complexity. The transaction suggests a strategic shift towards higher-margin offerings within the drug delivery and pharmaceutical packaging market.

Somewhat-Bullish (0.182)

Yahoo Finance Singapore•7/10/2026

ABBV: Neutral (0.143)

Relevance 0.858

West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business

West Pharmaceutical Services (WST) has sold the rights and facilities for its SmartDose 3.5 mL On Body Delivery System to AbbVie. This strategic move allows West Pharmaceutical Services to refocus its portfolio on other drug delivery offerings, particularly larger-volume platforms and high-value injectable solutions. The transaction aims to simplify the company's manufacturing footprint and enhance its competitive position in line with its growth areas.

Somewhat-Bullish (0.161)

ABBV: Neutral (0.116)

Relevance 0.841

GuruFocus•7/10/2026

ABBV Maintained by B of A Securities -- Price Target Raised to $276

B of A Securities analyst Geoff Meacham has maintained a 'Buy' rating for AbbVie (ABBV) and raised its price target to $276.00 from $234.00, reflecting increased confidence in the company's future performance. Despite the positive analyst outlook and strong GF Score™ of 76/100, the stock is currently considered 16.1% overvalued based on its GF Value™, with a P/E ratio significantly higher than its 5-year median. Investors are advised to weigh these factors carefully, as there has been no recent insider trading activity.

Bullish (0.491)

ABBV: Bullish (0.490)

TradingView•7/10/2026

AbbVie Inc. Stock 12‑Month Price Target Raised to $263.72, Implies 6% Upside

Analyst estimates have led to an increase in AbbVie Inc.'s average 12-month price target from $262.04 to $263.72, signaling a potential 6% upside from its latest closing price. The consensus rating among 32 analysts remains a "Buy," with a majority recommending the stock. This update provides investors with insights into the expected future performance of AbbVie Inc. based on expert analysis.

Bullish (0.431)

ABBV: Bullish (0.400)

TradingKey•7/10/2026

Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 7.27% on Jul 10: What Signal Does It Send?

Arrowhead Pharmaceuticals Inc. (ARWR) stock fell by 7.27% on July 10, driven by investor concerns about its late-stage clinical pipeline, intensified competition in RNAi therapeutics, and potential equity dilution. The company reported annual revenue of $829.45 million and a net loss of $1.63 million, with technical indicators showing mixed signals (MACD buy, RSI neutral, Williams %R buy). Analysts have an average price target of $90.90 for ARWR, despite risks like loss of long-term asset value due to a royalty agreement, high operational cash burn, and concentrated clinical risk.

Bearish (-0.383)

ABBV: Somewhat-Bearish (-0.305)

Relevance 0.621

Simply Wall Street•7/10/2026

Does EyePoint’s (EYPT) Broad Russell Index Debut Quietly Recast Its DURAVYU‑Centric Investor Base?

EyePoint (EYPT) was recently added to several Russell growth and small-cap indices, increasing its visibility to index-tracking and quantitative investors. Despite this, the company's investment narrative remains centered on the success of its lead product, DURAVYU, which is currently in Phase 3 trials for wet AMD. The index inclusion doesn't alter the critical near-term catalyst of DURAVYU's Phase 3 readouts, and the company still faces significant late-stage risk and a limited cash runway.

Neutral (0.015)

ABBV: Neutral (0.064)

Relevance 0.556

GuruFocus•7/10/2026

ABBV Maintains Overweight Rating -- Price Target Raised to $295

Wells Fargo analyst Mohit Bansal maintained an "Overweight" rating on AbbVie (ABBV) and raised its price target from $260 to $295. Despite this positive outlook, GuruFocus indicates that ABBV is currently 17.8% overvalued based on its GF Value™ of $212.14 compared to its current price of $249.91. The company holds a GF Score™ of 76/100, highlighting strong profitability and growth, but also notes that there has been no insider buying or selling activity in the past three months.

Bullish (0.377)

ABBV: Bullish (0.498)

MSN•7/10/2026

AbbVie to buy Apogee Therapeutics for $10.9 billion in cash

AbbVie announced its intent to acquire Apogee Therapeutics for $10.9 billion in cash. This acquisition is significant for AbbVie's portfolio, enhancing its presence in the therapeutics market through Apogee's pipeline. The deal highlights continued consolidation and strategic investment within the pharmaceutical industry.

Bullish (0.787)

marketscreener.com•7/10/2026

ABBV: Bullish (0.713)

Relevance 0.907

RBC Raises Price Target on AbbVie to $280 From $260, Keeps Outperform Rating

RBC Capital Markets has raised its price target for AbbVie Inc. (ABBV) shares to $280, up from $260, while maintaining an "Outperform" rating on the stock. This adjustment reflects a positive outlook on the pharmaceutical company. The announcement follows similar price target changes from other firms like Wells Fargo and JPMorgan, indicating growing analyst confidence in AbbVie's performance.

Bullish (0.426)

ABBV: Bullish (0.437)

www.marketscreener.com•7/10/2026

BofA Securities Adjusts AbbVie Price Target to $276 From $234

BofA Securities has raised its price target for AbbVie Inc. (ABBV) shares to $276, up from the previous $234. The adjustment reflects BofA's updated outlook on the pharmaceutical company, as reported on July 10, 2026. This news comes amidst several other analyst adjustments for AbbVie, with various firms setting new price targets.

Somewhat-Bullish (0.291)

ABBV: Somewhat-Bullish (0.285)

Yahoo Finance UK•7/9/2026

AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note

AbbVie (ABBV) stock closed down 1.12% at $249.91 despite broader market gains, underperforming the S&P 500, Dow, and Nasdaq. The drugmaker is set to report earnings on July 31, 2026, with anticipated EPS of $3.76 and revenue of $16.79 billion. While the stock has seen a 12.35% gain over the past month, analysts' recent revisions and the company's Zacks Rank #3 (Hold) suggest a cautious outlook, with its Forward P/E ratio higher than the industry average.

Neutral (0.008)

Simply Wall Street•7/9/2026

ABBV: Neutral (0.040)

Relevance 0.318

Precigen (PGEN) In Focus As Russell Removal Tests Its Undervalued Narrative

Precigen (PGEN) has been removed from several Russell indexes, which could impact its trading volumes and pricing despite strong recent stock performance. The company's stock is currently considered 55.3% undervalued by analysts, with a fair value estimate of $12.45, largely driven by the rapid uptake of its PAPZIMEOS treatment. However, its high P/B ratio of 98x compared to an industry average of 2.8x raises concerns about potential valuation risk, especially for a company that is still loss-making.

Neutral (0.140)

Aspen Daily News•7/9/2026

ABBV: Neutral (0.113)

Relevance 0.601

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Neurocrine Biosciences, Inc. announced its second quarter 2026 financial results conference call and webcast will take place on July 30, 2026, at 1:30 p.m. Pacific Time. The press release will be issued at 1:00 p.m. PT on the same day. Details for dial-in and webcast access are provided, with a replay available on their website.

Neutral (0.122)

ABBV: Neutral (0.118)

Relevance 0.641

Yahoo Finance•7/9/2026

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?

This article compares the Invesco Pharmaceuticals ETF (PJP) and the State Street SPDR S&P Biotech ETF (XBI) for investors seeking healthcare exposure. PJP offers a less volatile, concentrated pharmaceutical focus with a higher dividend yield, while XBI provides high-growth, equal-weighted biotechnology exposure at a lower cost, featuring significant small-cap stock representation. The article concludes that XBI is the better buy due to its long-term performance, despite its higher volatility and past maximum drawdown.

Somewhat-Bullish (0.199)

ABBV: Neutral (0.108)

Relevance 0.638

MarketWatch•7/9/2026

AbbVie Inc. stock outperforms competitors despite losses on the day

AbbVie Inc. (ABBV) shares fell 1.12% to $249.91, marking its fourth consecutive day of losses, despite a strong overall market performance where the S&P 500 and Dow Jones Industrial Average rose. The stock's decline occurred on a day when major indices saw gains.

Neutral (0.138)

ABBV: Neutral (0.146)

BioPharma Dive•7/9/2026

GSK ends brain drug alliance with Alector

GSK has terminated its collaboration with biotechnology company Alector for neurodegenerative disease drugs, following clinical setbacks for both experimental medicines. The original $2.2 billion deal, which marked GSK's return to neuroscience, saw its value decrease after one drug failed to significantly slow disease progression and another's trial was discontinued. This marks Alector's second major partnership to fail, leading to significant stock value loss and layoffs.

Bearish (-0.374)

ABBV: Somewhat-Bearish (-0.323)

Relevance 0.620

Yahoo Finance•7/9/2026

WST Completes SmartDose Sale to AbbVie to Focus on Core Growth

West Pharmaceutical Services (WST) has finalized the sale and transfer of its SmartDose 3.5mL On-Body Delivery System to AbbVie (ABBV) for $112.5 million. This divestiture allows West Pharmaceutical to streamline its product portfolio and reallocate resources towards higher-growth drug delivery technologies, particularly larger-volume on-body delivery solutions. The company aims to focus on its core drug delivery business and continue innovating with other SmartDose platforms, such as the 10mL system for larger-volume injectable medicines.

Bullish (0.446)

ABBV: Somewhat-Bullish (0.323)

Relevance 0.928

TradingView•7/9/2026

WST Completes SmartDose Sale to AbbVie to Focus on Core Growth

West Pharmaceutical Services (WST) has completed the sale of its SmartDose 3.5mL On-Body Delivery System to AbbVie (ABBV), a transaction valued at $112.5 million. This divestiture allows West Pharmaceutical to focus on higher-growth drug delivery technologies and its core business, including other SmartDose platforms like the 10mL system. The company's stock has shown a 28.5% gain year-to-date, and it maintains a Zacks Rank #2 (Buy).

Somewhat-Bullish (0.235)

European Medical Journal•7/9/2026

ABBV: Neutral (0.136)

Relevance 0.801

GSK ends Alector alliance as both lead assets fail

GSK has terminated its five-year neuroscience collaboration with Alector after two experimental antibody drugs, latozinemab and nivisnebart, failed in clinical trials for frontotemporal dementia and Alzheimer's disease, respectively. While GSK exits the partnership, it continues to pursue external innovation, as evidenced by its recent acquisition of Nuvalent and expanded alliances with Wave Life Sciences and Flagship Pioneering. This termination is Alector's second major partnership loss in 18 months, though the company still retains three wholly-owned clinical candidates, including an anti-amyloid antibody, showing potential for its longer-term pipeline.

Bearish (-0.548)

ABBV: Somewhat-Bearish (-0.204)

Relevance 0.646

Moomoo•7/9/2026

Guggenheim Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $261

Guggenheim has reiterated its Buy rating on AbbVie (ABBV.US) and increased its price target to $261. This adjustment reflects the firm's continued confidence in the pharmaceutical giant's performance and future outlook.

Bullish (0.423)

ABBV: Bullish (0.424)

Ad-hoc-news.de•7/9/2026

AbbVie stock trades steadily as investors weigh immunology and oncology pipeline

AbbVie Inc.'s stock reflects its profile as a large-cap pharmaceutical company, with investors focusing on its immunology and oncology franchises, impending patent transitions, and capital returns driven by cash flow. The company maintains a diversified revenue base with a strong pipeline in immunology, oncology, neuroscience, virology, and eye care, emphasizing R&D productivity and strategic acquisitions to counteract patent expiries. AbbVie is also a significant dividend payer, balancing shareholder returns with continuous investment in innovation.

Somewhat-Bullish (0.201)

ABBV: Somewhat-Bullish (0.237)

Simply Wall Street•7/9/2026

Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress

Teva Pharmaceutical Industries (NYSE:TEVA) is progressing its anti-IL-15 monoclonal antibody, TEV-408, into a Phase 2b trial for vitiligo, following positive Phase 1b results showing improved skin pigmentation and a good safety profile. This move signals Teva's shift towards higher-margin biopharmaceuticals beyond its generic drug business. The company has external support through a funding deal with Royalty Pharma and a Fast Track designation for TEV-408 in celiac disease, indicating the drug's potential across multiple immune conditions.

Somewhat-Bullish (0.211)

Simply Wall Street•7/9/2026

ABBV: Neutral (0.148)

Relevance 0.619

Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress

Teva Pharmaceutical Industries (TEVA) is progressing its TEV-408 antibody, an anti-IL-15 monoclonal antibody for vitiligo, into a Phase 2b trial following promising Phase 1b data showing improved skin pigmentation and a good safety profile. This move highlights Teva's strategic shift toward higher-margin biopharmaceuticals and addresses an unmet medical need in vitiligo treatment. Investors are watching how this development will impact Teva's future product mix and its position in immunology-driven therapies, especially as the company's financial flexibility is often flagged due to debt.

Somewhat-Bullish (0.231)

Simply Wall Street•7/8/2026

ABBV: Neutral (0.115)

Relevance 0.595

Moderna (MRNA) Settles Vaccine Patent Case With $950 Million Upfront Payment

Moderna has settled a patent dispute with Arbutus Biopharma and Genevant Sciences concerning the lipid nanoparticle technology used in its COVID-19 vaccine, agreeing to a $950 million upfront payment. This settlement resolves multi-year litigation, removes legal uncertainty, and allows Moderna to focus on its broader mRNA pipeline. Investors should consider the impact of this payment on Moderna's financials and its high valuation signals.

Neutral (0.088)

Simply Wall Street•7/8/2026

ABBV: Neutral (0.044)

Relevance 0.572

AbbVie (ABBV) Wins EU Approval For Tepkinly, Is The Stock Fully Valued?

AbbVie (ABBV) recently received EU approval for Tepkinly, fueling discussions about its stock valuation. While one common analyst narrative suggests the stock is fairly valued around $253.55, a discounted cash flow model by Simply Wall St indicates a significantly higher intrinsic value of $457.98 per share. The article highlights strong momentum for AbbVie's stock but also points out potential risks related to its concentrated portfolio and drug pricing pressures.

Somewhat-Bullish (0.299)

ABBV: Somewhat-Bullish (0.250)

Claim Depot•7/8/2026

AbbVie accused of hiding painful lump risk from Juvederm patients in new lawsuit

A new class action lawsuit alleges that AbbVie, the manufacturer of Juvederm dermal fillers, failed to disclose the potential for severe and disfiguring granulomas to form after injections. The lawsuit, filed by Christina Garcia, claims that AbbVie's warning labels misrepresent the nature and duration of these side effects, which can appear months or years later. The complaint highlights previous internal studies and scientific literature suggesting AbbVie's knowledge of these risks and the proinflammatory nature of Juvederm's ingredients.

Neutral (0.009)

ABBV: Neutral (0.004)

Relevance 0.308

Stock Titan•7/8/2026

Wellington-affiliates report 564,326 APGE shares (APGE) ownership update

Wellington Management-affiliated entities have filed a Schedule 13G/A, reporting beneficial ownership of 564,326 shares (0.91%) of Apogee Therapeutics, Inc. (APGE) common stock as of June 30, 2026. The filing indicates shared voting power of 452,388 shares and shared dispositive power of 564,326 shares across related Wellington entities. The ownership is held on behalf of clients of Wellington Investment Advisers, and no single client is reported to own more than 5% of the class.

Neutral (-0.108)

ABBV: Neutral (-0.119)

Relevance 0.554

Yahoo Finance•7/8/2026

Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?

H.C. Wainwright analyst Raghuram Selvaraju increased the price target for Genmab A/S (GMAB) to $40 from $38, reaffirming a Buy rating following positive Epkinly DLBCL-4 trial results and increased regulatory approval likelihood. Additionally, the European Commission approved marketing authorization for TEPKINLY for relapsed or refractory follicular lymphoma, further strengthening the company's market position. Genmab, a global biotechnology company, focuses on developing antibody-based therapies for cancer and other serious diseases, utilizing advanced AI and proprietary platforms.

Bullish (0.423)

ABBV: Somewhat-Bullish (0.343)

Relevance 0.634

Trefis•7/8/2026

AbbVie Stock Traded Its Old Story for New Growth. Here Is The Price.

AbbVie (ABBV) has successfully transitioned past the patent cliff of its blockbuster drug Humira, with new drugs Skyrizi and Rinvoq now driving significant growth. This shift has changed the company's narrative from one of survival to one of focused growth on key assets. While revenue is accelerating, investors should monitor AbbVie's net margin, which has compressed, to determine if this is a temporary effect of scaling new products or a new normal for profitability.

Somewhat-Bullish (0.292)

ABBV: Somewhat-Bullish (0.288)

Quartr•7/8/2026

AbCellera Biologics (ABCL) Stifel 2025 Healthcare Conference Summary

AbCellera Biologics (ABCL) has transitioned from a platform-focused partnership model to developing wholly owned clinical assets, with two assets now in the clinic and a third in IND-enabling studies. The company is primarily focused on its internal pipeline, including ABCL635 for hot flashes and ABCL575 for INI conditions, while also selectively evaluating new partnerships. AbCellera maintains a strong financial position with over CAD 500 million in cash and equivalents, plus nearly CAD 200 million in government funding, providing liquidity for at least three years of operations.

Somewhat-Bullish (0.249)

The Globe and Mail•7/8/2026

ABBV: Neutral (0.106)

Relevance 0.620

Abivax: Wall Street Catches Up to the Data

Shares of Abivax (NASDAQ: ABVX) surged over 40% after positive Phase 3 trial results for its ulcerative colitis drug, Obefazimod, and a successful $920 million share offering. Despite an initial dip due to a cancer-related safety signal, subsequent data reinforced the drug's safety and efficacy, making Wall Street bullish on Abivax's future in the significant ulcerative colitis market. The share offering, fully subscribed, signaled strong institutional confidence and provided capital for development, while the stock now approaches its all-time high amidst potential acquisition interest.

Somewhat-Bullish (0.178)